Universal Ibogaine Inc. (IBO.V)

CAD 0.03

(0.0%)

Operating Income Summary of Universal Ibogaine Inc.

Universal Ibogaine Inc.'s latest annual operating income in 2022 was 497.15 Thousand CAD , up 112.97% from previous year.
Universal Ibogaine Inc.'s latest quarterly operating income in 2023 Q3 was 68.08 Thousand CAD , up 146.97% from previous quarter.
Universal Ibogaine Inc. reported an annual operating income of -3.83 Million CAD in 2021, down -1000900.0% from previous year.
Universal Ibogaine Inc. reported an annual operating income of 383.00 CAD in 2020, up 101.13% from previous year.
Universal Ibogaine Inc. reported a quarterly operating income of -144.95 Thousand CAD for 2023 Q2, up 11.53% from previous quarter.
Universal Ibogaine Inc. reported a quarterly operating income of -163.83 Thousand CAD for 2023 Q1, down -274.26% from previous quarter.

Annual Operating Income Chart of Universal Ibogaine Inc. (2022 - 2018)

Historical Annual Operating Income of Universal Ibogaine Inc. (2022 - 2018)

Year	Operating Income	Operating Income Growth
2022	497.15 Thousand CAD	112.97%
2021	-3.83 Million CAD	-1000900.0%
2020	383.00 CAD	101.13%
2019	-33.86 Thousand CAD	-152.95%
2018	63.95 Thousand CAD	0.0%

Year	Operating Income	Operating Income Growth
2023 Q3	68.08 Thousand CAD	146.97%
2023 Q2	-144.95 Thousand CAD	11.53%
2023 Q1	-163.83 Thousand CAD	-274.26%
2022 Q1	-1.53 Million CAD	-8182.76%
2022 FY	497.15 Thousand CAD	112.97%
2022 Q4	-43.77 Thousand CAD	-125.77%
2022 Q3	169.89 Thousand CAD	-43.6%
2022 Q2	301.22 Thousand CAD	119.62%
2021 Q4	-18.53 Thousand CAD	-130.74%
2021 Q2	5490.00 CAD	-82.39%
2021 Q3	60.29 Thousand CAD	998.21%
2021 FY	-3.83 Million CAD	-1000900.0%
2021 Q1	31.18 Thousand CAD	-19.8%
2020 FY	383.00 CAD	101.13%
2020 Q4	38.88 Thousand CAD	164.29%
2020 Q3	14.71 Thousand CAD	434.9%
2020 Q2	-4393.00 CAD	-188.09%
2020 Q1	4987.00 CAD	133.42%
2019 Q1	-9329.00 CAD	59.14%
2019 FY	-33.86 Thousand CAD	-152.95%
2019 Q4	-14.92 Thousand CAD	-14.61%
2019 Q3	-13.02 Thousand CAD	-215.0%
2019 Q2	11.32 Thousand CAD	221.37%
2018 FY	63.95 Thousand CAD	0.0%
2018 Q4	-22.83 Thousand CAD	44.87%
2018 Q3	-41.41 Thousand CAD	-164.02%
2018 Q1	-178.95 Thousand CAD	-85.51%
2018 Q2	64.69 Thousand CAD	136.15%
2017 Q4	-96.47 Thousand CAD	0.0%

Peer Operating Income Comparison of Universal Ibogaine Inc.

Name	Operating Income	Operating Income Difference
Arch Biopartners Inc.	-3.35 Million CAD	114.818%
Covalon Technologies Ltd.	-4.48 Million CAD	111.075%
Hemostemix Inc.	-2.33 Million CAD	121.305%
Kane Biotech Inc.	-3.35 Million CAD	114.808%
MedMira Inc.	-1.94 Million CAD	125.569%
Marvel Biosciences Corp.	-2.31 Million CAD	121.439%
NervGen Pharma Corp.	-17.77 Million CAD	102.797%
XORTX Therapeutics Inc.	-6.38 Million CAD	107.79%